Table 2 Summary of population treated with MRg-reSBRT

Age, median (range)

69 (46–87)

Pts (lesion)

18 (25)

Sex

 Male

 Female

9 (50%)

9 (50%)

Primitive site of tumor

 Colorectal cancer

 Gynecologist cancer (ovary, uterine)

 Hepatocellular carcinoma

 Others

4 (23,1%)

8 (42,30%)

2 (7,7%)

4 (26,9%)

Irradiated metastatic Lesion reSBRT = 25

 Liver

 Perihepatic abdominal carcinosis

20(80%)

5(20%)

Timing between I and re-SBRT, months, mean (range)

8,5 (2–28)

Oligometastatic disease classification

 Metachronous oligorecurrence

 Metachronous oligoprogression

 Induced oligo persistence

4 (22,2%)

12 (66,6%)

2 (11,2%)

Gating treatment for lesion

Breath hold inspiration

Free breathing

18(70%)

7 (30%)

PTV volume (cm3), mean (range)

13,3 (3,6–34,9)

PTV Dose I SBRT liver, median dose (range), mean BED _α/β10

43,1 (24–50), 95

PTV Dose reSBRT liver, median dose (range), mean BED _α/β10

41,3 Gy (16–50), 93

Liver dose reSBRT (Gy), mean dose (range), mean EQD2

3,7 Gy (1,6–8 Gy), 3

Mean Follow up, months (range)

11 (3–34)

Toxicity at the mean Follow up

 GI Grade 0–1

 GI Grade 2

0

0